Inhibitors | Comment | Organism | Structure |
---|---|---|---|
4-(5-phenyl-3-[3-[3-(3-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase | Homo sapiens | |
4-(5-phenyl-3-[3-[3-(4-trifluoromethoxy-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase | Homo sapiens | |
4-(5-phenyl-3-[3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase | Homo sapiens | |
4-(5-phenyl-3-[3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | dual inhibitor of cyclooxygenase-2 and soluble epoxide hydrolase. Inhibitor shows the best pharmacokinetic profiles in both mice and rats. Following subcutaneous administration at 10 mg/kg, compound exhibits antiallodynic activity that is more effective than the same dose of either COX-2 inhibitor celecoxib or sEH inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid alone, as well as coadministration of both inhibitors | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P34913 | - |
- |
Mus musculus | - |
- |
- |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.0000005 | - |
pH 7.0, 30°C | Homo sapiens | 4-(5-phenyl-3-[3-[3-(4-trifluoromethoxy-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | |
0.0000009 | - |
pH 7.0, 30°C | Homo sapiens | 4-(5-phenyl-3-[3-[3-(4-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide | |
0.0000041 | - |
pH 7.0, 30°C | Homo sapiens | 4-(5-phenyl-3-[3-[3-(3-trifluoromethyl-phenyl)-ureido]-propyl]-pyrazol-1-yl)-benzenesulfonamide |